Prostate cancer vaccine shows promise in clinical trials

Share this article:
Dendreon's cancer vaccine Provenge has shown promise by extending the lives of patients with prostate cancer, according to a study released this week, the first time a cancer vaccine has been shown to improve survival in any malignancy.
Dendreon, a biotech based in Seattle, Wash., said it will wait for three-year data from an additional 98 patients, which it expects in the second half of this year, before seeking
FDA approval for the vaccine. If the data from that study also show a survival benefit, the company said it will begin discussions with the FDA.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.